Last updated: September 7, 2026
Actemra, Roche’s tocilizumab, is a mature biologic with broad immunology and hospital use. Its revenue peaked during COVID-19 treatment demand and has since declined as pandemic-related sales normalized and biosimilar competition entered the U.S. market. Roche retains substantial commercial value through multiple indications, subcutaneous and intravenous formulations, pediatric use, and established hospital purchasing relationships. The primary medium-term risk is erosion from tocilizumab biosimilars, led in the United States by Tofidence.
What is Actemra and how is it used?
Actemra is the brand name for tocilizumab, a humanized monoclonal antibody that blocks the interleukin-6 receptor. Roche markets the product as RoActemra outside the United States through Genentech and other Roche affiliates.
The FDA-approved indications include:
| Indication |
Primary patient group |
Main U.S. formulation or use |
| Rheumatoid arthritis |
Adults with moderately to severely active disease |
Intravenous and subcutaneous |
| Giant cell arteritis |
Adults |
Subcutaneous |
| Systemic sclerosis-associated interstitial lung disease |
Adults |
Intravenous and subcutaneous |
| Polyarticular juvenile idiopathic arthritis |
Patients age 2 and older |
Intravenous and subcutaneous |
| Systemic juvenile idiopathic arthritis |
Patients age 2 and older |
Intravenous and subcutaneous |
| Cytokine release syndrome |
Adults and pediatric patients |
Intravenous |
| COVID-19 |
Hospitalized adults and pediatric patients meeting FDA criteria |
Intravenous |
The FDA originally approved Actemra for rheumatoid arthritis in 2010. Later approvals expanded the product from chronic inflammatory disease into pediatric rheumatology, oncology-related cytokine release syndrome and selected hospitalized COVID-19 patients. These additional indications increased the value of the intravenous hospital channel, although COVID-19 demand was temporary. (FDA, 2024a)
How has Actemra revenue changed over time?
Actemra’s sales trajectory has three distinct phases: pre-pandemic immunology growth, COVID-19-driven acceleration, and post-pandemic normalization.
Roche reported Actemra/RoActemra sales of approximately CHF 2.6 billion in 2023, following higher pandemic-period demand. Sales were materially above the product’s pre-COVID baseline during 2021 and 2022, when hospitals used tocilizumab for certain critically ill COVID-19 patients. Roche’s annual reports identify lower COVID-19 demand and competitive pressure as factors affecting subsequent sales. (Roche, 2023; Roche, 2024)
| Period |
Financial trajectory |
Primary driver |
| Before 2020 |
Established multibillion-franc biologic franchise |
Rheumatology and hospital immunology |
| 2020 |
Increased demand |
Early COVID-19 treatment interest and expanded clinical use |
| 2021 |
Pandemic-related peak period |
Hospital use for severe COVID-19 and cytokine-driven disease |
| 2022 |
Elevated but normalizing sales |
Lower COVID-19 utilization and mature rheumatology demand |
| 2023 |
Approximately CHF 2.6 billion in Roche-reported sales |
Post-pandemic normalization and emerging biosimilar pressure |
| 2024 onward |
Downward pressure expected |
Biosimilar entry, price competition and fewer COVID-19 volumes |
The COVID-19 contribution had a disproportionate effect on the revenue base because it added acute-care demand to a product historically anchored in chronic rheumatology. That revenue was less durable than sales from rheumatoid arthritis, giant cell arteritis and juvenile idiopathic arthritis.
What is driving Actemra’s current market dynamics?
Actemra remains commercially relevant because it has a diversified indication base and two delivery routes. Its market dynamics are controlled by five factors.
First, rheumatoid arthritis is a mature but large market with several biologic and targeted synthetic alternatives, including TNF inhibitors, JAK inhibitors, abatacept and other interleukin-directed products. Actemra competes on clinical positioning, route of administration, physician familiarity and payer terms.
Second, the product has a differentiated role in cytokine release syndrome after CAR-T-cell therapy. This hospital-based use is connected to the growth of cellular immunotherapies. Demand in this segment is more closely tied to CAR-T treatment volumes than to routine rheumatology prescribing.
Third, giant cell arteritis and systemic sclerosis-associated interstitial lung disease extend Actemra’s addressable market. These indications support utilization beyond rheumatoid arthritis, but they do not eliminate payer substitution risk.
Fourth, the intravenous formulation has a hospital and infusion-center presence, while the subcutaneous formulation supports at-home administration. The two routes create different competitive and contracting dynamics.
Fifth, the product is exposed to biosimilar substitution. A biosimilar with a lower acquisition cost can win formulary preference even when the reference product retains strong physician recognition.
What is the FDA regulatory status of Actemra?
Actemra is an FDA-approved biologic licensed under section 351(a) of the Public Health Service Act. The product has approvals for adult and pediatric inflammatory diseases, cytokine release syndrome and selected COVID-19 treatment settings.
The FDA approved Actemra for COVID-19 in 2021 under a supplemental biologics license application after earlier emergency-use activity. The COVID-19 indication did not create a permanent high-growth market because treatment protocols, hospitalization rates and use of immunomodulators changed as the pandemic evolved. (FDA, 2021)
Actemra is supplied in intravenous and subcutaneous presentations. The intravenous product is administered in healthcare settings, while prefilled syringes and autoinjector presentations support outpatient use.
What biosimilars compete with Actemra?
The first FDA-approved U.S. tocilizumab biosimilar is Tofidence, developed by Bio-Thera Solutions and commercialized in the United States by Biogen. The FDA approved Tofidence in September 2023. It is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome in the applicable patient populations. (FDA, 2023)
| Product |
Developer or marketer |
U.S. status |
Commercial significance |
| Actemra |
Genentech/Roche |
Reference biologic |
Retains brand and contracting position |
| Tofidence |
Bio-Thera Solutions and Biogen |
FDA-approved biosimilar |
First direct U.S. tocilizumab biosimilar |
| Tyenne |
Fresenius Kabi |
Approved in certain non-U.S. markets and subject to regional regulatory development |
Expands international biosimilar pressure |
| Other tocilizumab biosimilars |
Regional manufacturers |
Market access varies by jurisdiction |
Increase price competition outside the U.S. |
Tofidence is not automatically interchangeable with Actemra under the FDA approval cited above. Substitution therefore depends on state pharmacy law, payer policy, institutional protocols and prescriber direction. Hospital systems can still use formulary controls and purchasing contracts to shift market share.
In Europe and other markets, biosimilar access is generally more advanced. National tender systems can produce faster price erosion than the U.S. commercial market, especially for intravenous hospital products.
When does Actemra lose exclusivity?
Actemra’s core biologic exclusivity is no longer the main barrier to competition. The FDA’s 12-year reference-product exclusivity period for a biologic approved in 2010 has expired. Biosimilar approvals are therefore permitted, subject to applicable patent and regulatory requirements.
The key commercial issue is no longer whether a biosimilar can be approved. It is whether the biosimilar can obtain favorable reimbursement, formulary placement and supply contracts.
| Exclusivity category |
Actemra position |
| FDA biologic reference-product exclusivity |
Expired |
| Small-molecule Hatch-Waxman exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not the principal Actemra protection |
| Pediatric exclusivity |
Product-specific and time-limited; not a long-term barrier |
| Patent protection |
Must be assessed by formulation, use, manufacturing and jurisdiction |
| Biosimilar competition |
Active in the United States and more developed in international markets |
What is the Orange Book status of Actemra?
The Orange Book is not the central patent database for Actemra because Actemra is a biologic licensed under the Public Health Service Act rather than a conventional small-molecule drug approved under an NDA.
Biologic reference products and biosimilars are primarily tracked through the FDA’s Purple Book. Patent and exclusivity analysis must therefore consider the biologics statute, FDA Purple Book entries, patent-office records, product labeling and court filings. The absence of a conventional Orange Book listing does not mean the product has no intellectual-property protection. It means the relevant framework differs from the Hatch-Waxman process used for small-molecule generics. (FDA, 2024b)
What patents protect Actemra?
Actemra’s original composition-of-matter protection for tocilizumab is mature. The remaining commercial protection is more likely to involve later-filed patents and regulatory exclusivity relating to:
- Subcutaneous delivery systems.
- Prefilled syringes and autoinjectors.
- Formulation stability.
- Concentration and excipient combinations.
- Dosing regimens.
- Specific indications.
- Manufacturing and cell-culture processes.
- Crystalline, protein-engineering or antibody-production features, where applicable.
The relevant patent estate is not equivalent to a single blocking patent. Biosimilar manufacturers can challenge patents, design around narrower claims or launch after relevant claims expire. The practical strength of each patent depends on claim scope, prosecution history, validity, enforceability and whether the patent can support injunctive relief or damages.
How strong is the Actemra patent estate?
Actemra’s patent estate is best characterized as mature rather than impenetrable. The original antibody protection no longer provides a durable barrier comparable to an early-stage biologic. Later formulation, delivery and method-of-use patents may delay or shape competition, but they generally provide narrower protection than a broad composition patent.
The strongest remaining commercial protections are likely to be:
- Product-specific regulatory know-how and manufacturing controls.
- Hospital and payer contracts.
- Formulation and device patents that affect particular presentations.
- Clinical familiarity in cytokine release syndrome and pediatric disease.
- Supply reliability for a complex monoclonal antibody.
These factors can preserve price and share after biosimilar entry, but they do not prevent eventual erosion.
Are there Paragraph IV challenges to Actemra?
Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule abbreviated new drug applications. It is not the standard legal route for a tocilizumab biosimilar.
A biosimilar sponsor instead proceeds under the Biologics Price Competition and Innovation Act. The process may include the statutory patent-information exchange, often called the patent dance, followed by patent litigation under the relevant federal statutes. The biosimilar sponsor may also pursue litigation over patents, licensing rights or launch timing.
For Actemra, the central competitive event is the FDA approval and commercialization of Tofidence rather than a conventional Paragraph IV generic filing. No broad Paragraph IV framework governs the product’s biosimilar entry.
What patent litigation affects Actemra?
The most important litigation risk concerns patent disputes between Roche affiliates and biosimilar manufacturers over product, formulation, delivery, manufacturing or method-of-use claims. The public commercial record through 2024 indicates that U.S. tocilizumab competition has advanced primarily through regulatory approval and market contracting rather than a widely reported, market-blocking patent judgment involving Tofidence.
The absence of a major injunction does not eliminate litigation risk. Biosimilar launches can proceed subject to patent settlements, licenses, covenants not to sue or agreed launch dates. Settlement terms are often confidential, limiting public visibility into the exact timing of competitive entry.
Which companies are challenging Actemra’s market position?
The principal challengers are biosimilar developers and manufacturers rather than branded immunology competitors alone.
| Company |
Competitive route |
Market impact |
| Biogen |
U.S. commercialization of Tofidence |
Direct U.S. biosimilar competition |
| Bio-Thera Solutions |
Tofidence developer |
Supplies biosimilar technology and product |
| Fresenius Kabi |
Tocilizumab biosimilar development and regional commercialization |
Adds hospital tender pressure |
| Regional biosimilar manufacturers |
National approvals and tenders |
Accelerate non-U.S. price erosion |
| AbbVie, Amgen, Johnson & Johnson, Bristol Myers Squibb and other immunology companies |
Competing biologics and targeted therapies |
Reduce Actemra share in chronic inflammatory diseases |
Competition differs by indication. In rheumatoid arthritis, Actemra competes against multiple established mechanisms. In cytokine release syndrome, the competitive set is narrower because tocilizumab is deeply embedded in treatment protocols associated with CAR-T therapy.
What generic or biosimilar launch scenarios exist?
Three scenarios are commercially relevant.
Base case: gradual erosion
Roche retains a majority of U.S. revenue for several years through brand loyalty, hospital contracting, pediatric use and supply reliability. Tofidence captures selected accounts, particularly where payers prioritize lower net cost.
Downside case: rapid hospital substitution
Health systems adopt Tofidence or other biosimilars as preferred products for intravenous use. Roche responds with discounts, reducing net price even where Actemra remains on formulary. The intravenous franchise declines faster than subcutaneous outpatient sales.
Resilient case: indication-specific retention
Actemra maintains stronger share in cytokine release syndrome, pediatric rheumatology and selected specialty centers. Biosimilars gain more rapidly in routine rheumatoid arthritis and hospital tenders than in complex or protocol-driven uses.
What is Actemra’s geographic market exposure?
The United States remains strategically important because it combines high biologic prices with substantial biosimilar potential. Europe has greater tender exposure and generally faster uptake of lower-cost biologics. Japan, South Korea and other developed Asian markets have their own reimbursement and substitution rules. Emerging markets are more price-sensitive but can produce volume growth through local manufacturing and government procurement.
Roche’s geographic exposure is therefore shifting from price-led growth toward volume retention, contracting and indication management. International biosimilar competition is likely to affect net price before it fully displaces branded volume.
How does Actemra compare with competing biologics?
| Factor |
Actemra |
TNF inhibitors |
JAK inhibitors |
Other IL-6 pathway products |
| Mechanism |
IL-6 receptor blockade |
TNF blockade |
Intracellular kinase inhibition |
Varies |
| Administration |
IV and subcutaneous |
Often subcutaneous or IV |
Oral |
Usually subcutaneous or IV |
| Biosimilar exposure |
Increasing |
High for older products |
Generally lower for newer products |
Varies |
| CRS role |
Established |
Limited |
Limited |
Product-specific |
| Hospital use |
Significant |
Variable |
Limited |
Variable |
| Price pressure |
Rising |
High in mature products |
Driven by payer controls and safety considerations |
Developing |
Actemra’s strongest differentiation is its established role in cytokine release syndrome and its broad pediatric and adult label. Its greatest weakness is exposure to a crowded chronic immunology market where payers can compare multiple mechanisms.
What are the revenue and investment risks?
The main revenue risks are:
- Continued decline in COVID-19-related demand.
- U.S. biosimilar discounting.
- European tender losses.
- Lower net prices caused by rebate competition.
- Substitution by newer immunology therapies.
- Manufacturing interruptions for a complex antibody product.
- Reduced use in rheumatoid arthritis as treatment algorithms evolve.
The main offsets are:
- CAR-T market growth supporting cytokine release syndrome use.
- Continued demand in giant cell arteritis.
- Expansion of systemic sclerosis-associated interstitial lung disease treatment.
- Pediatric indications with fewer direct substitutes.
- Roche’s manufacturing scale and global distribution.
- Potential retention of higher-value accounts through contracting.
Key Takeaways
- Actemra is a mature, multibillion-franc Roche biologic based on tocilizumab.
- Revenue rose during the COVID-19 period and has entered a post-pandemic decline.
- Roche reported approximately CHF 2.6 billion in Actemra/RoActemra sales in 2023.
- Tofidence, developed by Bio-Thera and commercialized by Biogen, is the first major U.S. tocilizumab biosimilar.
- The product’s 12-year biologic exclusivity period has expired.
- Patent risk now centers on formulations, delivery systems, dosing, manufacturing and method-of-use claims.
- Paragraph IV litigation is not the principal framework because Actemra is a biologic.
- The U.S. market will likely experience gradual-to-moderate erosion, while European tender markets face faster price pressure.
- Cytokine release syndrome, pediatric use and specialty indications provide the strongest defenses against rapid substitution.
- The long-term commercial outlook is declining revenue with residual strategic value in hospital immunology and cellular-therapy support.
FAQs
Is Actemra still a blockbuster drug?
Yes. Actemra remains a major biologic franchise, although its revenue is below the pandemic-period peak and is under pressure from biosimilars and mature immunology competition.
Is Tofidence interchangeable with Actemra?
The FDA approved Tofidence as a biosimilar, but the cited approval does not make it automatically interchangeable with Actemra. Substitution depends on regulatory designation, state law, payer policy and institutional practice.
Does Actemra have a small-molecule generic?
No. Actemra is a biologic. The relevant competitors are biosimilars, not conventional Hatch-Waxman generic drugs.
Which Actemra indication is most protected from biosimilar substitution?
Cytokine release syndrome associated with CAR-T therapy and certain pediatric uses may be more resistant to rapid substitution because of protocol integration, specialist oversight and hospital-specific treatment pathways.
Can Roche extend Actemra’s commercial life after biosimilar entry?
Roche can preserve value through formulation and device differentiation, contracting, manufacturing reliability, specialty-indication support and lifecycle management. These measures can slow erosion but are unlikely to restore pandemic-era growth.
References
-
European Medicines Agency. (2024). RoActemra: EPAR product information. https://www.ema.europa.eu/
-
Food and Drug Administration. (2021). FDA approves emergency use of Actemra for hospitalized adults and children with COVID-19. https://www.fda.gov/
-
Food and Drug Administration. (2023). FDA approves first biosimilar tocilizumab product, Tofidence. https://www.fda.gov/
-
Food and Drug Administration. (2024a). Actemra prescribing information. Genentech, Inc. https://www.accessdata.fda.gov/
-
Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Roche. (2023). Annual report 2023. F. Hoffmann-La Roche Ltd. https://www.roche.com/investors/annual-report
-
Roche. (2024). Annual report 2024. F. Hoffmann-La Roche Ltd. https://www.roche.com/investors/annual-report
